333404-66-3

Upstream product

• 3764-01-0 2,4,6-trichloropyrimidine 
• 104-94-9 4-methoxy-aniline 

Downstream Products

• 531504-19-5 6-chloro-N²,N²-bis-(4-methoxy-benzyl)-N⁴-(4-methoxy-phenyl)-pyrimidine-2,4-diamine 
• 1350641-45-0 C₁₅H₁₇ClN₄O 
• 1350641-46-1 C₁₇H₂₁ClN₄O 
• 1350641-09-6 C₂₅H₃₀N₆O 
• 1350641-10-9 C₂₂H₂₅N₅O₂ 
• 1350641-11-0 C₂₂H₂₅N₅O₂ 
• 1350641-12-1 C₂₄H₂₇F₂N₅O₂ 
• 1350641-13-2 C₂₄H₂₇F₂N₅O₂ 
• 1350641-14-3 C₂₄H₂₆F₃N₅O₂ 
• 1350641-15-4 C₂₄H₂₉N₅O₂ 
• 1350641-16-5 C₂₄H₂₆F₃N₅O₂ 
• 1251463-04-3 C₁₆H₁₅ClN₄O₂ 
• 1251463-00-9 6-chloro-N-furan-2-ylmethyl-N'-(4-methoxy-phenyl)-pyrimidine-2,4-diamine 
• 531504-20-8 6-cyclohexylmethoxy-N²,N²-bis-(4-methoxy-benzyl)-N⁴-(4-methoxy-phenyl)-pyrimidine-2,4-diamine 

Relevant academic research and scientific papers

Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2

GalR1 and GalR2 represent unique pharmacological targets for treatment of seizures and epilepsy. A novel series of 2,4,6-triaminopyrimidine derivatives were synthesized and found to have sub-micromolar affinity for GalR2. Optimization of a series of 2,4,6

ANTIVIRAL PYRIMIDINES

Disclosed herein are novel compounds comprising substituted pyrimidines, pyrazolopyrimtdines, and imidazolopyrimidines, the syntheses thereof, and compositions thereof, including pharmaceutical compositions, comprising the novel pyrimidines, pyrazolopyrimtdines, imidazolpyrimidines and related compounds. Such compounds function to inhibit entry of viruses of the Flaviviridae family, including Hepatitis C virus (HCV), into cells that are susceptible to virus infection. These compounds are useful for the treatment, therapy and/or prophylaxis of viral diseases and infection, including HCV infection.

4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.

The cyclin dependent kinase (cdk) inhibitor NU6027, 4-cyclohexylmethoxy-5-nitroso-pyrimidine-2,6-diamine (IC(50) vs cdk1/cyclinB1=2.9+/-0.1 microM and IC(50) vs cdk2/cyclinA3=2.2+/-0.6 microM), was used as the basis for the design of a series of 4-alkoxy-2,6-diamino-5-nitrosopyrimidine derivatives. The synthesis and evaluation of 21 compounds as potential inhibitors of cyclin-dependent kinases 1 and 2 is described and the structure-activity relationships relating to NU6027 have been probed. Simple alkoxy- or cycloalkoxy-groups at the O(4)-position were tolerated, with the 4-(2-methylbutoxy)-derivative (IC(50) vs cdk1/cyclinB1=12+/-2 microM and cdk2/cyclinA3=13+/-4 microM) retaining significant activity. Substitutions at the N(6) position were not tolerated. Replacement of the 5-nitroso substituent with ketone, oxime and semicarbazone groups essentially abolished activity. However, the derivative bearing an isosteric 5-formyl group, 2,6-diamino-4-cyclohexylmethoxy-pyrimidine-5-carbaldehyde, showed modest activity (IC(50) vs cdk1/cyclinB1=35+/-3 microM and cdk2/cyclinA3=43+/-3 microM). The X-ray crystal structure of the 5-formyl compound bound to cdk2 has been determined to 2.3A resolution. The intramolecular H-bond deduced from the structure with NU6027 bound to cdk2 is not evident in the structure with the corresponding formyl compound. Thus the parent compound, 4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine (NU6027), remains the optimal basis for future structure-activity studies for cyclin-dependent kinase inhibitors in this series.

2,4,6-Trichloropyrimidine. Reaction with anilines

The reaction of 2,4,6-trichloropyrimidine 1 with a variety of 4-substituted anilines 2 has been investigated. Monosubstitution occurs readily for all anilines except those containing strongly electron-withdrawing groups. The yields of the isomeric product